Influence of ESBL colonization status on gut microbiota composition during allogenic hematopoietic stem cell transplantation by Silvia Corcione, Ilario Ferrocino, Tommaso Lupia, Alessandro Busca, Gabriele Bianco, Chiara Dellacasa, Luisa Giaccone, Lucia Brunello, Sara Butera, Cristina Costa, Benedetto Bruno, Francesco Giuseppe De Rosa

“…The changes can be rapid and are thought to be caused by chemotherapy, antibiotics, or intestinal inflammation. …”
Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

“…Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing EGFR or ALK alterations, were aged 75 years or above, had a programmed cell death-ligand 1 tumor proportion score of less than 50%, had not undergone systemic chemotherapy, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. …”
Get full text

Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizu... by L. Johnetta Blakely, Sabine Oskar, Ian Kudel, Ashley Roush, Zoya Shamsi, Toni Perry, Annette Christianson, Brittni Smith, Thomas Burke

“…Methods: Adults with advanced NSCLC, ECOG performance status of 0–2, who received first-line (1L) pembrolizumab (monotherapy or with chemotherapy) were eligible. Those initiating pembrolizumab from 1 July 2017 to 30 June 2019, identified retrospectively (historical cohort), were compared with those initiating pembrolizumab from 1 October 2019 to 30 September 2021 who were prospectively offered Noona (standard of care [SoC] cohort). …”

Shaoyao Gancao decoction alleviates paclitaxel-induced cognitive impairment by activating PTEN/PI3K/AKT pathway to inhibit NETs formation by Xu Ying, Su Yue, Hu Yuwen, Li Xiang, Zhou Ziyan, Yuan Ningning, Ji Xiaowei, Jiang Ruoyu, Wang Wenzhu, Zhang Yafeng, Zhai Guojie, Cheng Xiaolan

“…Purpose: Paclitaxel-induced cognitive impairment (PICI) is a frequent and severe adverse reaction of chemotherapy. Increased neuroinflammation related to neutrophil extracellular traps (NETs) may play a key role in PICI. …”
Get full text

Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53 by Lingli Gong, Daxing Xu, Kaixiang Ni, Jie Li, Wei Mao, Bo Zhang, Zhening Pu, Xiangming Fang, Ying Yin, Li Ji, Jingjing Wang, Yaling Hu, Jiao Meng, Rui Zhang, Jiantong Jiao, Jian Zou

“…This results in enhanced tumor growth and resistance to chemotherapy, particularly in tumors with missense mutant p53. …”
Get full text

Assessment of prognosis and responsiveness to immunotherapy in colorectal cancer patients based on the level of immune cell infiltration by Kaili Liao, Minqi Zhu, Lei Guo, Zijun Gao, Jinting Cheng, Bing Sun, Yihui Qian, Bingying Lin, Jingyan Zhang, Tingyi Qian, Yixin Jiang, Yanmei Xu, Qionghui Zhong, Xiaozhong Wang

“…Furthermore, we identified distinct chemotherapy responses to 39 drugs between these risk subgroups.ConclusionThis study revealed a significant correlation between high levels of immune infiltration and unfavorable prognosis in patients with colon cancer. …”
Get full text

KiKli Fit: Insights into the Development and Practice of a Physical Activity Program in Pediatric Cancer by Lisa Hillebrech, Lars Rehbein, Ann Christin Schneider, Sara Müller, Christina Schindera, Katharina Eva, Valentin Benzing

“…However, they identified several barriers to participation, including medical constraints, chemotherapy administration, fatigue, visits, or lack of motivation. …”
Get full text

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial by Julian R Marchesi, Emma Nicholson, Benjamin H Mullish, Renuka Palanicawandar, Graham Wheeler, Francesca Kinsella, Andrew J Innes, Lauren A Roberts, Shian Anim-Burton, Lee Webber, Nicholas A Johnson, Rohma Ghani, Pakhshan Farshi, Anjum B Khan, Panagiotis Kottaridis, Pramila Krishnamurthy, Frances Davies, Jiří Pavlů

“…Most patients undergoing HCT for a haematological malignancy have previously received intensive chemotherapy, resulting in prolonged neutropenic episodes requiring broad-spectrum antibiotics; use of these has been linked to reduced microbiome diversity. …”
Get full text

Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects by Zhi-Xun Guo, Jia-Li Ma, Jin-Qiu Zhang, Ling-Ling Yan, Ying Zhou, Xin-li Mao, Xin-li Mao, Xin-li Mao, Shao-Wei Li, Shao-Wei Li, Shao-Wei Li, Xian-Bin Zhou, Xian-Bin Zhou, Xian-Bin Zhou

“…Current treatment modalities for esophageal cancer primarily include encompass chemotherapy and a limited array of targeted therapies, which are hampered by toxicity and drug resistance issues. …”
Get full text

Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 20... by V. T. Ivashkin, I. V. Mayev, T. L. Lapina, A. A. Sheptulin, A. S. Trukhmanov, R. A. Abdulkhakov, S. A. Alekseyenko, N. N. Dekhnich, R. S. Kozlov, I. L. Klyaritskaya, S. A. Kurilovich, M. F. Osipenko, V. I. Simanenkov, I. B. Khlynov

Get full text

Cardiovascular disease risk in cancer survivors: a population-based cohort study from the UK Biobank, and meta-analysis of cohort studies by Hong Li, Yazhou He, Zubing Mei, Hong Wu, Yang Shen, Ziqiang Wang, Jichun Zhao, Chuan Xu, Yanhong Zhou, Chi Shu, Botao Yu, Xiran Wang, Changtao Li, Yiqiang Liu

“…Evidence appraisal identified one convincing association between hematologic/lymphatic malignancies and ischaemic heart disease, along with 29 highly suggestive associations.Conclusions Our study provided comprehensive estimates of CVD incidence in cancer survivors and identified a significantly elevated CVD risk among patients with cancer, regardless of chemotherapy or radiotherapy. These findings underscore the need for routine assessment of CVD risk factors at cancer diagnosis to enhance the well-being and survival of patients with cancer.PROSPERO registration numberCRD42022307056…”
Get full text

European standard clinical practice recommendations for paediatric high-grade gliomas by Elwira Szychot, Géraldine Giraud, Darren Hargrave, Dannis van Vuurden, Jacques Grill, Veronica Biassoni, Maura Massimo, André O. Von Büren, Rejin Kebudi, Maria João Gil-da-Costa, Sophie Veldhuijzen van Zanten, Simon Bailey, Michael Karremann, Stephanie Bolle, Thankamma Ajithkumar, Mechthild Krause, Yasmin Lassen-Ramshad, Geert Janssens, Giovanni Morana, Ulrike Löbel, Shivaram Avula, Brigitte Bison, Maarten Lequin, Kristian Aquilina, Ulrich Thomale, Pelle Nilsson, Sami Bui-Quy Abu Hamdeh, Torsten Pietsch, Pascale Varlet, Thomas S. Jacques, Pieter Wesseling, David Jones, Uri Tabori, Anirban Das, David Mulligan, Francesca Kozmann, Christof M. Kramm

“…Much of the evidence for the use of chemotherapy in pedHGGs is extrapolated from adult data, and the evidence for its use in the paediatric population is still weak. …”
Get full text

PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma by Genevieve Douglas, Zoe Loh, Evonne S.Y. Shum, Sze-Ting Lee, Niamh Waters, Garry Hamilton, Geoffrey Chong, Alexandra C. Murphy, Eliza A. Hawkes

“…Our study aimed to evaluate whether CACS obtained from pretreatment positron emission tomography (PET)/computed tomography (CT) scans could stratify cardiac event risk in patients with lymphoma receiving anthracycline-based chemotherapy. We enrolled 358 consecutive patients with lymphoma treated between 2012 and 2022, calculating the CACS from their pretreatment PET/CT. …”
Get full text

Evaluating the radiosensitivity of the oral microbiome to predict radiation-induced mucositis in head and neck cancer patients: A prospective trial by Andreas R. Thomsen, Elsa Beatriz Monroy Ordonez, Michael Henke, Benedikt Luka, Jörg Sahlmann, Henning Schäfer, Vivek Verma, Nadine Schlueter, Anca-Ligia Grosu, Tanja Sprave

“…The vast majority of patients received adjuvant RT and concurrent chemotherapy. Overall, 34 (58.6 %) participants developed grade 3 OM after a median dose of 32 Gy. …”
Get full text

Self‐Boosting Programmable Release of Multiple Therapeutic Agents by Activatable Heterodimeric Prodrug‐Enzyme Assembly for Antitumor Therapy by Shanshan Jiang, Bhaskar Gurram, Junfei Zhu, Shan Lei, Yifan Zhang, Ting He, Oya Tagit, Hui Fang, Peng Huang, Jing Lin

“…Thereupon, the enzymatic activity of GOx is recovered; ii) GOx‐triggered pH reduction further facilitates the dissociation of NTP@GOx, thus accelerating a large amount of NTP and GOx release; iii) The TK linker of prodrug NTP is cleaved by hydrogen peroxide generated by GOx catalysis, thus expediting the release of NBS for Type‐I photodynamic therapy and PTX for chemotherapy, respectively. The NTP@GOx shows great potential for multimodal synergistic cancer therapy.…”
Get full text

Natural Product Identification and Molecular Docking Studies of Leishmania Major Pteridine Reductase Inhibitors by Moses N. Arthur, George Hanson, Emmanuel Broni, Patrick O. Sakyi, Henrietta Mensah-Brown, Whelton A. Miller, Samuel K. Kwofie

“…This enzyme catalyzes the NADPH-dependent reduction of pterins to their tetrahydro forms. While chemotherapy remains the primary treatment, its effectiveness is constrained by drug resistance, unfavorable side effects, and substantial associated costs. …”
Get full text

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression by Jianfeng Peng, Xueying Zhai, Xiaomei Liu, Zhaoqin Huang, Yimeng Wang, Peizhu Wu, Ran Gao, Xiangjiao Meng

“…Methods: A retrospective analysis was conducted on patients with ES-SCLC who experienced disease progression after receiving programmed cell death ligand 1 (PD-L1) inhibitors combined with standard chemotherapy as first-line treatment at three sites in China. …”
Get full text

Collagen turnover biomarkers to predict outcome of patients with biliary cancer by Leonard Kaps, Muhammed A. Genc, Markus Moehler, Stephan Grabbe, Jörn M. Schattenberg, Detlef Schuppan, Rasmus Sund Pedersen, Morten A. Karsdal, Philipp Mildenberger, Annett Maderer, Nicholas Willumsen

“…Methods We measured the seven biomarkers of collagen turnover in sera of 72 patients with BTC at baseline and after first and second chemotherapy cycle (CTX). Markers were also assessed in sera of 50 healthy controls and compared to levels of patients at baseline. …”
Get full text

Whole lung radiomic features are associated with overall survival in patients with locally advanced non-small cell lung cancer treated with definitive radiotherapy by Meng Yan, Zhen Zhang, Jia Tian, Jiaqi Yu, Andre Dekker, Dirk de Ruysscher, Leonard Wee, Lujun Zhao

“…Methods A total of 661 patients with LA-NSCLC treated with definitive radiotherapy in combination with chemotherapy were enrolled in this study, with 292 patients in the training set, 57 patients from the same hospital from January to December 2017 as an independent test set (test-set-1), 83 patients from a multi-institutional prospective clinical trial data set (RTOG0617) as test-set-2, and 229 patients from a Dutch radiotherapy center as test-set-3. …”
Get full text

L-glutaminase synthesis by Klebsiella pneumoniae (AS KP 23) isolated from clinical strain, and its efficacy against human hepatocellular and breast cancer cell lines by Lina J. Abdel-Hafez, Eman Y. T. Elariny, Asmaa E. Ibrahim, Mahmoud E. F. Abdel-Haliem

“…L-glutaminase has been cited as the most potent molecule that inhibits the proliferation of cancer cells, which significantly raises the possible applicability of cancer therapy and the possibility of its application as an alternative drug to chemotherapy. The first investigation into the antitumor property of L-glutaminase revealed its inhibitory effect on the growth of Gardner lymphosarcoma (6C3HED) and L-1210 leukemia cells. …”
Get full text